{"id":17477,"date":"2019-10-23T09:02:42","date_gmt":"2019-10-23T09:02:42","guid":{"rendered":"https:\/\/www.bensnaturalhealth.com\/blog\/?p=17477"},"modified":"2026-07-29T10:26:40","modified_gmt":"2026-07-29T10:26:40","slug":"testosterone-and-prostate-cancer","status":"publish","type":"post","link":"https:\/\/www.bensnaturalhealth.com\/blog\/prostate-health\/testosterone-and-prostate-cancer\/","title":{"rendered":"Does Testosterone Increase Prostate Cancer Risk?"},"content":{"rendered":"

Most men asking this question have either been offered TRT or are worried their testosterone levels are somehow linked to prostate cancer. Here’s the short answer: current evidence doesn’t support the idea that normal or supplemented testosterone causes prostate cancer to develop or progress in most men. But it’s a more complex picture than a simple yes or no.<\/span><\/p>\n

This article is informational and not a substitute for medical advice. Talk to your doctor or a urologist before making any decisions about TRT.<\/span><\/p>\n

What the Research Actually Shows<\/b><\/h2>\n

The data on whether testosterone increases prostate cancer risk has shifted over the past decade. Older assumptions that testosterone fuels prostate tumors the way fuel feeds fire have given way to a more complicated picture, shaped by receptor biology rather than simple hormone levels.<\/span><\/p>\n

The evidence in human studies<\/b><\/h3>\n

Large reviews consistently find that TRT does not raise the incidence of new prostate cancer. A 2025 scoping review in the<\/span> International Journal of Impotence Research<\/span><\/a> analyzed 12 studies published between 2005 and 2025 and found no increased risk of biochemical recurrence or cancer progression in men who received TRT after definitive treatment.<\/span><\/p>\n

A 2024 meta-analysis of<\/span> 28 RCTs (3,461 patients) TRT prostate-safe<\/span><\/a> confirmed that TRT did not affect prostate cancer progression or benign prostatic hyperplasia. These are randomized controlled trials, the strongest tier of human evidence.<\/span><\/p>\n

Perhaps the most counterintuitive finding in this space is that men with chronically low testosterone may actually face worse outcomes. A 2025 study in <\/span>Cancer Medicine<\/span><\/i> found that<\/span> low testosterone AHR 2.70 prostate cancer death<\/span><\/a> in men with minimal comorbidity, meaning low testosterone, not high, correlated with more aggressive disease. A 2025 review in <\/span>International Journal of Urology<\/span><\/i> supports this, noting that low testosterone associates with higher Gleason scores and poorer prognosis, though whether it causes those worse outcomes or simply reflects them isn’t yet resolved. Understanding<\/span> what causes prostate cancer<\/span><\/a> more broadly helps put these hormone findings in context, as does reviewing the full range of<\/span> prostate cancer risk factors<\/span><\/a> that carry independent predictive weight.<\/span><\/p>\n

One important caveat: most study follow-up spans 5 to 10 years. Very long-term data, beyond a decade, is still limited, so absolute certainty over 20-plus-year horizons isn’t yet possible.<\/span><\/p>\n

A 2026 BSSM consensus statement (<\/span>reviewed here<\/span><\/a>) analyzed 167 men on TRT versus 6,658 controls on active surveillance. The TRT reduced conversion hazard HR 0.66 compared with untreated men, meaning those receiving TRT were actually less likely to need escalation to active treatment. A 2025 review of clinical evidence in <\/span>International Journal of Urology<\/span><\/i> (<\/span>full paper<\/span><\/a>) draws similar conclusions. The BSSM statement also appears in the<\/span> World Journal of Men’s Health<\/span><\/a>.<\/span><\/p>\n

What doesn’t prove causation<\/b><\/h3>\n

The historical belief that testosterone fuels prostate cancer growth came from one important observation: androgen deprivation therapy (ADT), which strips testosterone from the body, slows the disease. Logically, some concluded, more testosterone must do the opposite.<\/span><\/p>\n

But correlation isn’t causation. ADT works because prostate cancer cells depend on androgen receptor (AR) signaling; blocking that signal starves the tumor. That tells us receptors matter, not that normal circulating testosterone independently causes cancer to form or spread in eugonadal men. The relationship between low testosterone and more aggressive disease is equally correlative. It could be that aggressive tumors themselves suppress testosterone production, rather than low testosterone driving aggressiveness. That question remains open.<\/span><\/p>\n

Why This Question Matters<\/b><\/h2>\n

Prostate cancer is the most commonly diagnosed cancer in men, with an estimated<\/span> 313,780 new prostate cancer cases in 2025<\/span><\/a> in the United States alone. The<\/span> 98% five-year prostate cancer survival rate<\/span><\/a> for localized disease is reassuring, yet the fear of doing anything that might worsen the odds is completely understandable.<\/span><\/p>\n

Meanwhile, millions of men have hypogonadism and stand to benefit from TRT. Globally, there’s a<\/span> 13-fold variation in global prostate cancer incidence<\/span><\/a> across regions, which strongly suggests that genetics, diet, and environment, not testosterone, are the main drivers.<\/span><\/p>\n

Concerns about whether TRT raises risk are especially common among men who carry a family history or genetic risk.<\/span> Is prostate cancer hereditary?<\/span><\/a> is a question worth exploring separately, as is the distinct issue of<\/span> prostate cancer in young men<\/span><\/a> and their specific risk profile.<\/span><\/p>\n

How Testosterone and Prostate Cancer May Be Connected<\/b><\/h2>\n

The saturation model is the leading framework for understanding why testosterone and prostate cancer don’t have a simple linear relationship. It has real clinical applications for how doctors think about TRT safety.<\/span><\/p>\n

The testosterone-prostate growth link<\/b><\/h3>\n

The saturation model proposes that prostate tissue, including cancer cells, has a finite number of androgen receptors (AR). Below roughly 150 to 250 ng\/dL of serum testosterone, those receptors aren’t fully occupied, and the prostate responds strongly to any increase in androgen. Once receptors are saturated, adding more testosterone doesn’t produce meaningful additional stimulation. The gas pedal is already floored.<\/span><\/p>\n

This is why ADT causes tumor regression: you drop testosterone far below the saturation point, and the signal the cancer depends on collapses. But raising testosterone from, say, 200 ng\/dL to 600 ng\/dL in a man already above saturation threshold? The receptors are already occupied. The Mayo Clinic’s<\/span> review of this mechanism<\/span><\/a> explains it clearly for patients.<\/span><\/p>\n

The catch is individual variation. AR sensitivity differs between men, and the exact saturation threshold may shift depending on receptor density and genetic AR variants. A foundational collaborative analysis of 20 prospective studies found that<\/span> low free testosterone associated with lower overall cancer risk<\/span><\/a> (OR 0.76 for low-grade disease), but a nonsignificantly higher risk of high-grade disease, a grade-specific pattern the saturation model alone doesn’t fully explain.<\/span><\/p>\n

As the prostate changes with age, so does the clinical picture; learning<\/span> what happens to your prostate as you age<\/span><\/a> helps put normal androgen-related changes in perspective.<\/span><\/p>\n

Existing cancer and hormone exposure<\/b><\/h3>\n

If you already have prostate cancer, or carry high risk, the calculus shifts. Most major professional organizations, including the American Urological Association, don’t recommend TRT for men with active, untreated prostate cancer. The consensus is clear: TRT shouldn’t be started while cancer is uncontrolled.<\/span><\/p>\n

For men on active surveillance with low- or intermediate-risk disease, or those who’ve completed definitive treatment and show no evidence of recurrence, many guidelines now consider selective TRT under close monitoring to be cautiously permissible. A 2022 article examining TRT in advanced disease flags the unknowns that still remain for that population and urges caution. For patients undergoing radiotherapy with high-risk disease, a 2025 study examined<\/span> clinical tolerance of TRT over two years<\/span><\/a>, suggesting tolerability is possible but that the evidence base stays limited. Another analysis notes that<\/span> testosterone therapy in advanced disease<\/span><\/a> carries too many unresolved questions for routine use outside carefully monitored trials.<\/span><\/p>\n

What Your Doctor Wants You to Know<\/b><\/h2>\n

A clinician discussing TRT with you is thinking about far more than cancer risk alone. They’re weighing symptom burden, baseline PSA, biopsy history, and comorbidities.<\/span><\/p>\n

Risk factors that matter more<\/b><\/h3>\n

The established prostate cancer risk factors (age over 50, Black race, first-degree family history, BRCA2 mutation) carry far more predictive weight than testosterone levels. Current evidence doesn’t show that any specific age group, racial group, or genetic subgroup has a meaningfully different prostate cancer risk from TRT compared with the general population, though studies in high-risk subgroups remain limited.<\/span><\/p>\n

Lifestyle matters too.<\/span> Smoking ties to more aggressive prostate cancer<\/span><\/a>.<\/span> Excess weight raises risk<\/span><\/a>, while a<\/span> Mediterranean diet may be protective<\/span><\/a>. Some research suggests<\/span> frequent ejaculation may reduce risk<\/span><\/a>. These are all modifiable factors worth discussing with your doctor, well ahead of hormone management. A broader proactive approach to<\/span> prostate cancer prevention<\/span><\/a> pulls many of these levers together.<\/span><\/p>\n

A 2026 systematic meta-analysis of 41 RCTs found that TRT<\/span> did not significantly raise cardiovascular or prostate cancer risk<\/span><\/a> when administered properly. An earlier systematic review published in <\/span>Prostate Cancer and Prostatic Diseases<\/span><\/i> reached<\/span> similar conclusions about TRT and prostate cancer<\/span><\/a>. An active clinical trial (NCT06733350) is currently<\/span> examining TRT in men on active surveillance<\/span><\/a>, which will add meaningful long-term data. A 20-year meta-analysis on<\/span> testosterone replacement and cardiovascular risk<\/span><\/a> rounds out the safety picture.<\/span><\/p>\n

When testosterone therapy needs monitoring<\/b><\/h3>\n

Before starting TRT, your doctor will check serum total testosterone (typically requiring a level below 300 ng\/dL with symptoms), along with a baseline PSA and often a digital rectal exam. Once you’re on TRT, PSA is usually rechecked every three months in the first year, then every six to twelve months thereafter.<\/span><\/p>\n

A PSA rise above 1.0 ng\/mL within the first year, or a confirmed PSA velocity above 0.75 ng\/mL per year, is a standard trigger for reassessment and potentially a biopsy referral. If you’re already on TRT and a prostate issue is detected, the standard approach is to pause therapy, investigate fully, and re-evaluate TRT’s appropriateness based on what’s found. It’s also worth understanding how<\/span> castration-resistant prostate cancer<\/span><\/a> develops, since it’s useful background for anyone managing advanced hormone-related disease.<\/span><\/p>\n

Men with hypogonadism also face broader metabolic consequences;<\/span> testosterone and diabetes<\/span><\/a> share a bidirectional relationship in which low androgen levels are associated with impaired insulin sensitivity, adding another reason to address deficiency under medical supervision.<\/span><\/p>\n

Red Flags and When to See a Doctor<\/b><\/h2>\n

Some symptoms warrant prompt evaluation regardless of your TRT status.<\/span><\/p>\n

See your doctor soon if you notice:<\/span><\/p>\n